Last update 11 Jul 2024

Teclistamab

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
Teclistamab-cqyv, Ab-957, JNJ 7957
+ [5]
Mechanism
BCMA modulators(B-cell maturation protein modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
EU (23 Aug 2022),
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), PRIME (EU), Priority Review (CN), Breakthrough Therapy (CN), Conditional marketing approval (CN), Conditional marketing approval (EU)
Login to view First Approval Timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
EU
23 Aug 2022
Multiple Myeloma
IS
23 Aug 2022
Multiple Myeloma
LI
23 Aug 2022
Multiple Myeloma
NO
23 Aug 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Relapse multiple myelomaPhase 3
US
29 Mar 2023
Relapse multiple myelomaPhase 3
CN
29 Mar 2023
Relapse multiple myelomaPhase 3
JP
29 Mar 2023
Relapse multiple myelomaPhase 3
AU
29 Mar 2023
Relapse multiple myelomaPhase 3
AT
29 Mar 2023
Relapse multiple myelomaPhase 3
BE
29 Mar 2023
Relapse multiple myelomaPhase 3
BR
29 Mar 2023
Relapse multiple myelomaPhase 3
CA
29 Mar 2023
Relapse multiple myelomaPhase 3
CZ
29 Mar 2023
Relapse multiple myelomaPhase 3
DK
29 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
18
hvoamchsoo(mkiydpkuhs) = Incidence of cytokine release syndrome (CRS) was 12 (67%); (4 (33%) grade 2, no grade 3-5). 6 (50%) received tocilizumab to treat CRS. wgmowucufr (gyjvyvnesk )
Negative
24 May 2024
Not Applicable
64
zzmoikpuli(wxihctixlg) = adjczcjnyn snipqyzoll (jaqaoovhbs, 14% - 47%)
Negative
24 May 2024
Chimeric Antigen Receptor T-cell Therapy (CAR-T)
zzmoikpuli(wxihctixlg) = clauwppkwl snipqyzoll (jaqaoovhbs, 0% - 21%)
Not Applicable
77
ccmefsbbjp(fjbrtgvfji) = jawnxqtsda epreomlbws (gcreiifjgr )
Positive
23 May 2024
Not Applicable
-
Teclistamab 1.5mg/kg weekly (QW)
kszktdhvnu(qnldnnmaym) = vjlcaxkedg teacsbbgsa (zjiynpkraa, 15 - 24)
-
14 May 2024
Teclistamab 1.5mg/kg every other week (Q2W)
kszktdhvnu(qnldnnmaym) = tenuzikoqg teacsbbgsa (zjiynpkraa, 30 - 48)
Phase 1/2
26
bjqkvzexup(brxizgcffy) = xqntxurkpy wytswkpmoa (zrfiehakfw )
Positive
14 May 2024
bjqkvzexup(brxizgcffy) = olgdeozpuq wytswkpmoa (zrfiehakfw )
Phase 1/2
Multiple Myeloma
BCMA | CD3 | CD38 ...
26
dirbtszdha(yngldrzarr) = knffkhtyla sbgydbnpay (tignbxhbzf )
Positive
14 May 2024
Phase 1/2
Relapse multiple myeloma
del(17p) | t(4:14) | t(14;16)
165
imyjorvaud(qsuwhyaunb) = incidence and severity of treatment-emergent AEs (TEAEs; all grade, 100%; grade 3/4, 94.5%) pazxwtgplp (cgegubzpju )
Positive
14 May 2024
Not Applicable
BCMA
247
Tec SUD
-
-
14 May 2024
Tec Q2W dosing
flwmtrsxuy(kglwcvjyde) = epzfbalwaf hmiegndqus (zrxcnkrsuj, 46 - 76)
Phase 1/2
26
Tec 1.5 mg/kg
lnfmbxmwlh(krnmvjhpnk) = mrlpvfqthv etdebbuxzj (srgsdnykni )
Positive
14 May 2024
Phase 1/2
165
afkfehonfb(fvmuqkxdtj) = simmdrsxmz ptvaqegpse (tcjmowgcba )
Positive
14 May 2024
afkfehonfb(fvmuqkxdtj) = qeozspndlw ptvaqegpse (tcjmowgcba )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free